Biotech Values

[jq1234]

I don't think anyone can explain away the no OS benefit trend issue unless new trial result shows other wise. Read his contradictions:

Prior to vintafolide, no drug has demonstrated an improvement in either survival or delayed disease progression.

OK, if this is true, then why should the below matter?

The control arm received more post-study therapy than treatment arm

Plus, below is true to both PFS and OS, but only PFS benefit, no OS benefit trend (not asking stat significance here, just trend):

First, the study used a 2:1 randomiziation, so we had 100 patients in the treatment arm and only 49 in the control arm, so a much smaller sample for the ccntrol arm.

So the only point left is this, but no one knows whether this WAS affecting OS benefit:

and the control arm patients had a better prognosis than the treatment arm